Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 920 of 6351
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis is a prospective, phase 2, multicenter, open-label, single-arm study. Primary objective is to assess the efficacy of loncastuximab tesirine given as consolidation therapy after salvage immunochemotherapy in BTKi (Bruton Tyrosine Kinase inhibitors) -treated (or BTKi intoleran…
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New cocktail aims to outsmart pancreatic Cancer's defenses
Disease control OngoingThe purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease. The names of the study drugs involved in this study are: * 9-ING-41 * Losartan * Ferumoxytol * FOLFI…
Phase 2 • Sponsor: Colin D. Weekes, M.D., PhD • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New steroid hope for duchenne boys: safer muscle treatment?
Disease control CompletedThis Phase II study is an open-label, multiple dose study to evaluate the safety, tolerability, PK, PD, clinical efficacy, behavior and neuropsychology, and physical functioning vamorolone over a treatment period of 12 weeks in steroid-naïve boys ages 2 to \<4 years, and glucocor…
Phase 2 • Sponsor: Santhera Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Sound waves zapping skin cancer? new trial tests HIFU for basal cell carcinoma
Cure OngoingThe overall objective of this study is to demonstrate the safety and efficacy of removal of Basal Cell Carcinoma (BCC) using a new investigational equipment based on high-intensity focused ultrasound. Basal cell carcinoma is the most common cancer in Europe, Australia and the U.…
Sponsor: Joergen Serup • Aim: Cure
Last updated Jun 27, 2026 07:53 UTC
-
New precision approach could revolutionize osteoporosis care
Disease control OngoingOsteoporosis affects 24.5% of women over 65 and results in fracture-related hospital admissions exceeding those of heart attacks, strokes and breast cancer combined. Current treatment options do not account for differences between age-related and estrogen deficiency related osteo…
Phase 4 • Sponsor: Madhumathi Rao • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Nudge, nudge: simple texts could curb diabetes epidemic
Prevention OngoingA large body of research has demonstrated that intensive lifestyle interventions and metformin are effective treatments to prevent or delay diabetes among high-risk adults, yet neither treatment is routinely used in practice. The Behavioral Nudges for Diabetes Prevention (BEGIN) …
Sponsor: Northwestern University • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
New pill targets Hard-to-Treat lung cancer in patients who Can't have standard therapy
Disease control Recruiting nowOpen-label, non-randomised, exploratory, phase II, multi-centre clinical trial. 43 unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of induction treatment of AMG510 (Sotorasib) plu…
Phase 2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Immunotherapy combo shows promise in rectal cancer after standard treatment
Disease control OngoingThis study will evaluate the efficacy and safety of atezolizumab plus tiragolumab or atezolizumab alone following neoadjuvant chemoradiotherapy (nCRT) in participants with locally advanced rectal cancer (LARC). The study consists of a safety run-in phase and a randomization phase…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Experimental CAR-T therapy shows promise in small leukemia trial
Disease control CompletedThis is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with relapsed and refractory acute B-cell leukemia
Phase 1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill combo shows promise in slowing advanced breast cancer
Disease control CompletedThis is a Phase III, a randomized, double-blind, parallel , multi-center trail to evaluate the efficacy and safety of TQB3616 capsules plus fulvestrant compared to placebo plus fulvestrant in participants with estrogen receptor-positive, HER2-Negative Advanced Breast Cancer. Appr…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug sotatercept tested to slow PAH progression
Disease control Stopped earlyThe objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension \[PAH\] therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants w…
Phase 3 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug may scratch the itch for dialysis patients
Symptom relief CompletedThe purpose of this study was to evaluate the efficacy of nemolizumab compared to placebo at reducing the intensity of pruritus after a 12-week treatment period in adult hemodialysis participants with moderate to severe pruritus.
Phase 2/3 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Wrist zap may tame tics: electrical pulses tested as Drug-Free option
Symptom relief CompletedTourette syndrome (TS) and chronic tic disorder (CTD) are neurodevelopmental disorders that impact approximately 1% of 5-18 year olds worldwide. Both TS and CTD are characterised by the presence of tics, which are repetitive, purposeless, movements or vocalisations of short durat…
Sponsor: Nottingham University Hospitals NHS Trust • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Can tracking muscle changes unlock better duchenne treatments?
Knowledge-focused CompletedImproved standards of care and the regular early use of glucocorticoid treatment have changed the natural history of Duchenne muscular dystrophy (DMD), affecting both survival and time of loss of functional milestones. More recently, there has been increasing evidence of an addit…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Spinal stimulation may tame blood pressure swings after injury
Disease control Recruiting nowThis project will focus on a novel approach to stabilizing blood pressure (BP) during inpatient rehabilitation after acute SCI. After SCI, people have unstable blood pressure, ranging from too low (orthostatic hypotension) to too high (autonomic dysreflexia). Unstable BP often in…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Could a new drug tame dangerous brain blood vessel clusters?
Disease control CompletedThis is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic cerebral cavernous malformation (CCM).
Phase 2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a common schizophrenia drug curb violent acts? new trial aims to find out
Disease control Recruiting nowTwo-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU…
Phase 4 • Sponsor: New York State Psychiatric Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for kids with psoriatic arthritis: apremilast trial begins
Disease control Recruiting nowThe study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a tiny eye implant replace daily glaucoma drops?
Disease control CompletedTo assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Phase 2 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Double vision for heart stents: could two scans beat one?
Disease control OngoingThe COMBINE-INTERVENE Trial will investigate whether a PCI revascularization strategy based on combined FFR and OCT assessment is superior to a PCI revascularization strategy based on FFR-alone in patients with MVD with any presentation.
Sponsor: Diagram B.V. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC